A recent study reveals that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle plans.
Research printed in a prominent medical journal demonstrates that while overweight people can lose about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications must be cognizant of the danger of quick weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass in about a year and a half.
Weighing Therapies
The study, which looked at dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting.
Researchers point out that people who lose weight through lifestyle changes alone typically see a more gradual weight regain—approximately 100 grams monthly—once they finish.
Explaining the Quick Rebound
Doctors believe the way of the injections explains the accelerated weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone concentrations far above than normal may cause the system to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the treatment should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the long-term nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the jabs explain a sudden return of appetite.
"It felt as if a switch that goes on and I was suddenly extremely hungry," described a patient.
The struggle is worsened if patients have not developed permanent lifestyle or habit modifications during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Use is more common among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success hinges on integrated lifestyle changes.
